In a highly unusual move, the UK pharmaceutical industry’s trade body has suspended the membership of Danish diabetes giant Novo Nordisk (NOV: N).
It is only the eighth time in the past 40 years that the Association of the British Pharmaceutical Industry (ABPI) has taken such a strict measure.
The suspension, which will be in place for two years, is due to what the group calls “serious breaches” of its code of practice.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze